- Home
- RERE vs SLS Comparison
RERE vs SLS Comparison
Compare RERE & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | SLS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 924.5M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RERE | SLS |
|---|---|---|
| Price | $4.56 | $13.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 847.4K | ★ 5.7M |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | $110.98 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.50 | $1.39 |
| 52 Week High | $6.47 | $15.88 |
Technical Indicators
Market Signals| Indicator | RERE | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 59.05 |
| Support Level | $4.31 | $12.00 |
| Resistance Level | $4.83 | $15.88 |
| Average True Range (ATR) | 0.18 | 0.84 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 68.75 | 95.87 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.